Craig Brelsford
Hello. This is Craig Brelsford with Redchip Companies. Thank you for joining today’s event with TransCode Therapeutics, which trades on the NASDAQ under the ticker RNAZ. Joining us today is Philippe Calais, Chairman and CEO of TransCode; Zdravka Medarova, Co-Founder and Chief Scientific Officer; and John Tattory, the Interim CFO.
We will begin with a brief presentation in a moment, and then we will open the event to your questions. Welcome to everyone joining us today on X, YouTube, LinkedIn and other social media platforms.
[Operator Instructions]
Before we begin, please allow me to read the safe harbor statement. This call may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements pertaining to future financial and/or operating results, along with other statements about the future expectations, beliefs, goals, plans or prospects expressed by management constitute forward-looking statements. Any statements that are not historical facts should also be considered forward-looking statements. Of course, forward-looking statements involve risks and uncertainties.
Philippe, please go ahead.
Philippe Calais
CEO & Executive Chairman of the Board
Great. Thank you very much, and hello, everybody. It’s a pleasure to have the opportunity to describe our company today. And let’s jump in right away into the company overview. We really describe ourselves as a rare small cap company with 3 near-term catalysts. First of all, we have a very strong pedigree with some Harvard founders, and Z is one of them. She will be talking later on from Mass General and Harvard Medical School.
Credit: Source link
